Global Blood Shoots 17% Higher As Q2 Earnings Beat Estimates; Analyst Upgrades Stock
Global Blood Therapeutics Inc (NASDAQ:GBT) reported Q2 Oxbryta (voxelotor) sales of $47.55 million, +51% Y/Y, beating the consensus of $43.84…
The Daily Biotech Pulse: Pfizer’s Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)
Truist Securities Upgrades Global Blood Therapeutics to Buy, Raises Price Target to $50
Truist Securities analyst Joon Lee upgrades Global Blood Therapeutics (NASDAQ:GBT) from Hold to Buy and raises the price target from $45 to $50.
Global Blood Therapeutics Q2 EPS $(1.12) Beats $(1.19) Estimate, Sales $47.55M Beat $43.84M Estimate
Global Blood Therapeutics (NASDAQ:GBT) reported quarterly losses of $(1.12) per share which beat the analyst consensus estimate of $(1.19) by 5.88 percent. This is a 30.23 percent decrease over losses of $(0.86) per
Earnings Scheduled For August 3, 2021
Companies Reporting Before The Bell
• Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter.
• Stellantis (NYSE:STLA) is expected to report earnings for its second quarter.
Stocks That Hit 52-Week Lows On Friday
Before 10 a.m. ET Friday, 117 stocks made new 52-week lows.